High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: Analysis of a two-year, double-blind, randomized, controlled clinical trial

Arthritis and Rheumatism

Volumn 42, Issue 6, 1999, Pages 1194-1203

  Clements, Philip J ^a,t   Furst, Daniel E ^b   Wong, Weng Kee ^c   Mayes, Maureen ^d   White, Barbara ^e   Wigley, Fredrick ^f   Weisman, Michael H ^g   Barr, Walter ^h   Moreland, Larry W ⁱ   Medsger Jr , Thomas A ^j   Steen, Virginia ^k   Martin, Richard W ^l   Collier, David ^m   Weinstein, Arthur ⁿ   Lally, Edward ^o   Varga, John ^p   Weiner, Steven ^a   Andrews, Brian ^q   Abeles, Micha ^r   Seibold, James R ^s  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BENAROYA RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d HUTZEL HOSPITAL   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h LOYOLA UNIVERSITY CHICAGO   (United States)

ⁱ UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^j UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^k GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^l MICHIGAN STATE UNIVERSITY   (United States)

^m DENVER HEALTH MEDICAL CENTER   (United States)

ⁿ GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^o BROWN UNIVERSITY   (United States)

^p UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^q UNIVERSITY OF CALIFORNIA   (United States)

^r UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^s ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^t UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PENICILLAMINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG THERAPY; FEMALE; FLU LIKE SYNDROME; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYASTHENIA GRAVIS; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RASH; SCLERODERMA; SCORING SYSTEM; SKIN MANIFESTATION; STOMATITIS; SURVIVAL RATE; SYSTEMIC SCLEROSIS; THICKNESS;

ADULT; ANTIRHEUMATIC AGENTS; CREATINE KINASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; PENICILLAMINE; QUESTIONNAIRES; SCLERODERMA, SYSTEMIC; SKIN; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0033064099     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199906)42:6<1194::AID-ANR16>3.0.CO;2-7     Document Type: Article

References (24)

1. Harris ED, Sjoerdsma A. Effect of penicillamine on human collagen and possible application to treatment of scleroderma. Lancet 1966;2:996-9.
2. Fulghum DD, Katz R. Penicillamine for scleroderma. Arch Dermatol 1968;98:51-2.
3. Bluestone R, Grahame R, Holloway V, Holt PJ. Treatment of systemic sclerosis with D-penicillamine: a new method of observing the effects of treatment. Ann Rheum Dis 1970;29:153-8.
4. Winkelmann RK, Kierland RR, Perry HD, Muller SA, Sams WM Jr. Management of scleroderma. Mayo Clin Proc 1971;46:128-34.
5. Tio H, van Wikk L, Haan E. Treatment of progressive systemic sclerosis (PSS) with penicillamine: preliminary report of two cases. Acta Med Scand 1973;193:477-80.
6. Herbert CM, Lindberg KA, Jayson MI, Bailey AJ. Biosynthesis and maturation of skin collagen in scleroderma, and effect of D-penicillamine. Lancet 1974;1:187-92.
7. Asboe-Hansen G. Treatment of generalized scleroderma with inhibitors of connective tissue formation. Acta Derm Venereol 1975:55:461-5.
8. Zachariae H, Petersen HO, Zachariae E. D-penicillamine in scleroderma: a preliminary study. In: Munthe E, editor. Penicillamine research in rheumatoid disease. Oslo: Fabritius and Sonner; 1976. p. 290.
9. Jayson MIV, Lovell C, Black CM, Wilson RS. Penicillamine therapy in systemic sclerosis. Proc R Soc Med 1977;70 Suppl 3:82-8.
10. Mellstedt H, Fagrell B, Bjokholm M. Effect on nutritional capillary circulation. Scand J Rheumatol 1977;6:92-6.
11. Steen VD, Medsger TA Jr, Rodnan GP. D-penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis. Ann Intern Med 1982;97:652-9.
12. Jimenez SA, Sigal SH. A 15-year prospective study of treatment of rapidly progressive systemic sclerosis with D-penicillamine. J Rheumatol 1991;18:1496-503.
13. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
14. Medsger TA Jr, Steen VD. Classification, prognosis. In: Clements PJ, Furst DE, editors. Systemic sclerosis. Baltimore: Williams and Wilkins; 1996. p. 51-64.
15. Clements PJ, Lachenbruch PA, Seibold JR, White B, Weiner S, Martin RW, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281-5.
16. Poole JL, Steen VD. The use of the Health Assessment Questionnaire (HAQ) to determine physical disability in systemic sclerosis. Arthritis Care Res 1991;4:27-31.
17. Crapo RO, Morris AH. Standardized single breath normal values of carbon monoxide diffusing capacity. Am Rev Respir Dis 1981;123:185-9.
18. Morris JF, Koski A, Johnson LC. Spirometric standards for healthy non-smoking adults. Am Rev Respir Dis 1971;103:57-67.
19. Goldman HJ, Becklake MR. Respiratory function tests: normal values at median altitudes and the prediction of abnormal results. Am Rev Respir Dis 1959;79:457-67.
20. Schoenfeld DA. Sample-size formula for the proportional-hazards regression model. Biometrics 1983;39:499-503.
21. Clements P, Lachenbruch P, Furst D, Paulus H. The course of skin involvement in systemic sclerosis over three years in a trial of chlorambucil versus placebo. Arthritis Rheum 1993;36:1575-9.
22. White B, Bauer EA, Goldsmith LA, Hochberg MC, Katz LM, Korn JH, et al. Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. Arthritis Rheum 1995;38:351-60.
23. Netter P, Bannworth B, Peare P, Nicolas A. Clinical pharmacokinetics of D-penicillamine. Clin Pharmacokinet 1987;13:317-33.
24. Tett SE. Clinical pharmacokinetics of slow acting anti-rheumatic drugs. Clin Pharmacokinet 1993;25:392-407.